Compass Therapeutics, Inc. Common Stock
Symbol: CMPX (NASDAQ)
Company Description:
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
- Today's Open: $0
- Today's High: $0
- Today's Low: $0
- Today's Volume: 0
- Yesterday Close: $3.52
- Yesterday High: $3.61
- Yesterday Low: $3.45
- Yesterday Volume: 1.65M
- Last Min Volume: 0
- Last Min High: $0
- Last Min Low: $0
- Last Min VWAP: $0
- Name: Compass Therapeutics, Inc. Common Stock
- Website: https://www.compasstherapeutics.com
- Listed Date: 2020-11-13
- Location: BOSTON, MA
- Market Status: Active
- CIK Number: 0001738021
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $603.94M
- Round Lot: 100
- Outstanding Shares: 171.57M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-08-21 | SCHEDULE 13G/A | View |
2025-08-18 | SCHEDULE 13D/A | View |
2025-08-15 | SCHEDULE 13D/A | View |
2025-08-14 | SCHEDULE 13G/A | View |
2025-08-14 | SCHEDULE 13G/A | View |
2025-08-14 | SCHEDULE 13G/A | View |
2025-08-13 | SCHEDULE 13G | View |
2025-08-13 | 8-K | View |
2025-08-13 | 424B5 | View |
2025-08-12 | SCHEDULE 13G/A | View |
2025-08-12 | 424B5 | View |
2025-08-11 | 10-Q | View |
2025-08-11 | 8-K | View |
2025-07-16 | SCHEDULE 13G/A | View |
2025-06-12 | 8-K | View |
2025-05-27 | 4 | View |
2025-05-15 | SCHEDULE 13G/A | View |
2025-05-08 | 10-Q | View |
2025-05-08 | 8-K | View |
2025-04-29 | DEFA14A | View |